Current therapies and new developments in NASH

Jean François Dufour, Quentin M. Anstee, Elisabetta Bugianesi, Stephen Harrison, Rohit Loomba, Valerie Paradis, Herbert Tilg, Vincent Wai Sun Wong, Shira Zelber-Sagi

Research output: Contribution to journalReview articlepeer-review


Non-Alcoholic steatohepatitis is becoming the most important aetiology for advanced liver disease. There has been important progress in the field in recent years and the complexity of the pathophysiology of NASH is better understood. Multiple non-invasive circulating and imaging biomarkers have been tested. The importance of lifestyle has been recognised and several drugs are being tested in clinical trials. This review addresses the challenges that healthcare professionals face in the management of NASH patients.

Original languageEnglish
Pages (from-to)2123-2134
Number of pages12
Issue number10
Early online date16 Jun 2022
StatePublished - 1 Oct 2022

Bibliographical note

Publisher Copyright:

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Current therapies and new developments in NASH'. Together they form a unique fingerprint.

Cite this